In this lecture, recent scientific evidence on the optimum treatment of rheumatoid arthritis (RA) in primary care will be addressed. Despite substantial research effort many aspects of how to best manage RA are at dispute. This includes the role of non-biologic disease-modifying drugs (nbDMARDs) versus biologic DMARDs (bDMARDs) in early as well as in established disease. Conflicting data exist as to whether nbDMARD should be used in monotherapy or in combination. Also, recent studies questionmark the role of glucocorticoids as well as their route of administration.
With recent guidelines, tight disease control is central. This opens for a shift in focus from type of drug to treatment strategy with interesting implications for routine care, which will be discussed. It is, however, a challenge to meet the treatment goals in routine care. One question is how patient-reported outcomes and web-solutions may aid the rheumatologist in this effort? Recent studies have demonstrated that also economic and regulatory barriers in different countries challenge the rheumatologist both in primary and in secondary care.
These and other questions, which are highly relevant for the treatment of RA, will be presented and discussed.
Disclosure of Interest None Declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.